AU2017246794B2 - Anti-complement factor Bb antibodies and uses thereof - Google Patents

Anti-complement factor Bb antibodies and uses thereof Download PDF

Info

Publication number
AU2017246794B2
AU2017246794B2 AU2017246794A AU2017246794A AU2017246794B2 AU 2017246794 B2 AU2017246794 B2 AU 2017246794B2 AU 2017246794 A AU2017246794 A AU 2017246794A AU 2017246794 A AU2017246794 A AU 2017246794A AU 2017246794 B2 AU2017246794 B2 AU 2017246794B2
Authority
AU
Australia
Prior art keywords
antibody
seq
amino acid
present disclosure
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017246794A
Other languages
English (en)
Other versions
AU2017246794A1 (en
Inventor
Tony SangYoung BYUN
Karen Sue Christopherson
Sandip PANICKER
Graham Parry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AU2017246794A1 publication Critical patent/AU2017246794A1/en
Assigned to GENZYME CORPORATION reassignment GENZYME CORPORATION Request for Assignment Assignors: BIOVERATIV USA INC.
Application granted granted Critical
Publication of AU2017246794B2 publication Critical patent/AU2017246794B2/en
Priority to AU2024224000A priority Critical patent/AU2024224000A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017246794A 2016-04-04 2017-04-03 Anti-complement factor Bb antibodies and uses thereof Active AU2017246794B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024224000A AU2024224000A1 (en) 2016-04-04 2024-09-30 Anti-complement factor BB antibodies and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
US62/317,897 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024224000A Division AU2024224000A1 (en) 2016-04-04 2024-09-30 Anti-complement factor BB antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2017246794A1 AU2017246794A1 (en) 2018-10-25
AU2017246794B2 true AU2017246794B2 (en) 2024-07-04

Family

ID=60000646

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017246794A Active AU2017246794B2 (en) 2016-04-04 2017-04-03 Anti-complement factor Bb antibodies and uses thereof
AU2024224000A Pending AU2024224000A1 (en) 2016-04-04 2024-09-30 Anti-complement factor BB antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024224000A Pending AU2024224000A1 (en) 2016-04-04 2024-09-30 Anti-complement factor BB antibodies and uses thereof

Country Status (23)

Country Link
US (3) US10934347B2 (enExample)
EP (1) EP3452510A4 (enExample)
JP (4) JP6967528B2 (enExample)
KR (2) KR20240096672A (enExample)
CN (2) CN116790614A (enExample)
AU (2) AU2017246794B2 (enExample)
BR (1) BR112018070357A2 (enExample)
CA (1) CA3019332A1 (enExample)
CL (1) CL2018002810A1 (enExample)
CO (1) CO2018010827A2 (enExample)
CR (1) CR20180529A (enExample)
DO (1) DOP2018000219A (enExample)
EA (1) EA201892225A1 (enExample)
EC (1) ECSP18082302A (enExample)
IL (3) IL311675A (enExample)
MA (1) MA44878A (enExample)
MX (2) MX2018012176A (enExample)
MY (1) MY194603A (enExample)
PE (1) PE20190209A1 (enExample)
PH (1) PH12018502137A1 (enExample)
SG (1) SG11201808525UA (enExample)
TN (1) TN2018000341A1 (enExample)
WO (1) WO2017176651A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543257A1 (en) 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
IL266988B2 (en) * 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER
WO2018136455A1 (en) * 2017-01-17 2018-07-26 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
CN111727243A (zh) 2017-12-19 2020-09-29 北卡罗来纳-查佩尔山大学 用于跨越血-脑屏障递送病毒载体的方法和组合物
JP2022540768A (ja) * 2019-06-27 2022-09-20 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｃｄ５３組成物及び方法、ならびにその使用
US11820814B2 (en) * 2019-07-17 2023-11-21 Gemini Therapeutics Sub, Inc. Factor H potentiating antibodies and uses thereof
WO2021167949A1 (en) * 2020-02-18 2021-08-26 Children's Hospital Medical Center Compositions and methods for treating liver disease
PH12022552558A1 (en) 2020-04-20 2024-04-22 Genzyme Corp Humanized anti-complement factor bb antibodies and uses thereof
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
DE69526377T2 (de) 1994-12-09 2002-11-07 Microscience Ltd Virulenzgene in der VGC2-Region von Salmonella
US5939045A (en) 1994-12-22 1999-08-17 Nissan Chemical Industries, Ltd. Organic bismuth derivatives for X-ray imaging
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
PT939647E (pt) 1996-08-27 2002-04-29 Chiron Corp Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
JP2001525470A (ja) 1997-12-12 2001-12-11 マクロメド・インコーポレーテッド タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール）
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
EP1713503B1 (en) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Inhibition of factor b, the alternative complement pathway and methods related thereto
CN102532321B (zh) 2004-06-18 2018-10-12 Ambrx公司 新颖抗原结合多肽和其用途
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
HUE039865T2 (hu) * 2005-12-20 2019-02-28 Sbi Biotech Co Ltd Anti-ILT7 antitest
WO2007071061A1 (en) * 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
US8981060B2 (en) * 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
CA2704973A1 (en) * 2007-11-08 2009-05-14 Genentech, Inc. Anti-factor b antibodies and their uses
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
EP2483307A1 (en) 2009-09-29 2012-08-08 Fraunhofer USA, Inc. Influenza hemagglutinin antibodies, compositions, and related methods
EP2755688A4 (en) 2011-10-27 2014-08-06 Nkt Therapeutics Inc HUMANIZED ANTIBODIES AGAINST INKT
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
JP6244350B2 (ja) * 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
WO2014044793A2 (en) * 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
PL2914291T3 (pl) * 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
MX2015010682A (es) 2013-02-22 2016-05-31 Stemcentrx Inc Nuevos conjugados de anticuerpos y usos de los mismos.
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
KR20160126054A (ko) 2014-02-27 2016-11-01 알러간, 인코포레이티드 보체 인자 Bb 항체
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
PH12022552558A1 (en) 2020-04-20 2024-04-22 Genzyme Corp Humanized anti-complement factor bb antibodies and uses thereof

Also Published As

Publication number Publication date
IL295288A (en) 2022-10-01
CR20180529A (es) 2019-03-21
MY194603A (en) 2022-12-06
BR112018070357A2 (pt) 2019-01-29
KR102673420B1 (ko) 2024-06-07
SG11201808525UA (en) 2018-10-30
JP2026069789A (ja) 2026-04-24
WO2017176651A1 (en) 2017-10-12
KR20240096672A (ko) 2024-06-26
MA44878A (fr) 2019-03-13
US20210221877A1 (en) 2021-07-22
KR20190003951A (ko) 2019-01-10
PH12018502137A1 (en) 2019-09-23
JP7326393B2 (ja) 2023-08-15
AU2024224000A1 (en) 2024-12-19
IL295288B2 (en) 2024-08-01
IL311675A (en) 2024-05-01
ECSP18082302A (es) 2019-01-31
JP2023139289A (ja) 2023-10-03
CL2018002810A1 (es) 2019-03-15
CN109563158B (zh) 2022-08-09
MX2023007149A (es) 2023-06-28
CN116790614A (zh) 2023-09-22
MX2018012176A (es) 2019-02-07
EP3452510A1 (en) 2019-03-13
CN109563158A (zh) 2019-04-02
TN2018000341A1 (en) 2020-06-15
IL295288B1 (en) 2024-04-01
AU2017246794A1 (en) 2018-10-25
US11851482B2 (en) 2023-12-26
JP2021191789A (ja) 2021-12-16
EA201892225A1 (ru) 2019-09-30
US10934347B2 (en) 2021-03-02
IL262010B (en) 2022-09-01
CO2018010827A2 (es) 2018-11-22
JP6967528B2 (ja) 2021-11-17
IL262010A (en) 2018-10-31
NZ747018A (en) 2025-05-02
US20240228599A1 (en) 2024-07-11
PE20190209A1 (es) 2019-02-07
EP3452510A4 (en) 2020-01-15
CA3019332A1 (en) 2017-10-12
JP2019513726A (ja) 2019-05-30
US20190153079A1 (en) 2019-05-23
DOP2018000219A (es) 2019-03-31

Similar Documents

Publication Publication Date Title
US11851482B2 (en) Anti-complement factor Bb antibodies and uses thereof
EP2914291B1 (en) Anti-complement c1s antibodies and uses thereof
CA3124553A1 (en) Anti-complement c1s antibodies and uses thereof
US20260008852A1 (en) Anti-B7-H3 Antibody and Methods of Use Thereof
US12534537B2 (en) Anti-CD38 antibody and methods of use thereof
US20230265187A1 (en) Anti-tigit antibody and methods of use thereof
HK40063408A (en) Anti-complement c1s antibodies and uses thereof
HK40006720A (en) Anti-complement factor bb antibodies and uses thereof
NZ786930A (en) Anti-complement factor Bb antibodies and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GENZYME CORPORATION

Free format text: FORMER APPLICANT(S): BIOVERATIV USA INC.

FGA Letters patent sealed or granted (standard patent)